Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5773-5777

  Sidique, Shyama ^a,b   Shiryaev, Sergey A ^b   Ratnikov, Boris I ^b   Herath, Ananda ^a,b   Su, Ying ^a,b   Strongin, Alex Y ^b   Cosford, Nicholas D P ^a,b  

^a Conrad Prebys Center for Chemical Genomics ^*  (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Antiviral; Flavivirus; NS2B NS3 proteinase; Proteinase inhibitors; West Nile virus

Indexed keywords

BUFFER; PROTEINASE INHIBITOR; PYRAZOLE DERIVATIVE; VIRUS ENZYME;

ARTICLE; CHEMICAL REACTION; DRUG DESIGN; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; WEST NILE FLAVIVIRUS;

ALLOSTERIC REGULATION; ANTIVIRAL AGENTS; DRUG DESIGN; HALF-LIFE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; PYRAZOLES; RNA HELICASES; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; WEST NILE FEVER; WEST NILE VIRUS;

FLAVIVIRUS; WEST NILE VIRUS;

EID: 69949096730     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.150     Document Type: Article

References (16)

1. Campbell G.L., Marfin A.A., Lanciotti R.S., and Gubler D.J. Lancet Infect. Dis. 2 (2002) 519
2. Van der Meulen K.M., Pensaert M.B., and Nauwynck H.J. Arch. Virol. 150 (2005) 637
3. Hayes C.G. Ann. N. Y. Acad. Sci. 951 (2001) 25
4. Bera A.K., Kuhn R.J., and Smith J.L. J. Biol. Chem. 282 (2007) 12883
5. Ekonomiuk D., Su X., Ozawa K., Bodenreider C., Lim S.P., Yin Z., Keller T.H., Beer D., Patel V., Otting G., Caflisch A., and Huang D. PLoS Negl. Trop. Dis. 3 (2009) 356
6. Tomlinson S.M., and Watowich S.J. Biochem 47 (2008) 11763
7. Stoermer M.J., Chappell K.J., Liebscher S., Jensen C.M., Gan C.H., Gupta P.K., Xu W., Young P.R., and Fairlie D.P. J. Med. Chem. 51 (2008) 5714
8. Mueller N.H., Pattabiraman N., Ansarah-Sobrinho C., Viswanathan P., Pierson T.C., and Padmanabhan R. Antimicrob. Agents Chemother 52 (2008) 3385
9. Chappell K.J., Stoermer M.J., Fairlie D.P., and Young P.R. Curr. Med. Chem 15 (2008) 2771
10. Johnston P.A., Phillips J., Shun T.Y., Shinde S., Lazo J.S., Huryn D.M., Myers M.C., Ratnikov B., Smith J.W., Su Y., Dahl R., Cosford N.D.P., Shiryaev S.A., and Strongin A.Y. Assay. Drug Dev. Technol. 5 (2007) 737
11. Myers M.C., Napper A.N., Motlekar N., Shah P.P., Chiu C., Beavers M.P., Diamond S.L., Huryn D.M., and Smith III A.B. Bioorg. Med. Chem. Lett. 17 (2007) 4761
12. +.
13. 50 values were determined using routine kinetics software.
14. Charton M. J. Am. Chem. Soc. 91 (1969) 619
15. Charton M. J. Am. Chem. Soc. 91 (1969) 624
16. Sviridov S.I., Vasil'ev A.A., and Shorshnev S.V. Tetrahedron 63 (2007) 12195